



Clinical trial results:

A Combined Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Induction and Maintenance Study Evaluating the Safety and Efficacy of GS-5745 in Subjects with Moderately to Severely Active Ulcerative Colitis

Summary

EudraCT number	2014-005217-24
Trial protocol	HU CZ SK BG GB AT DE BE NL LV SE ES IE IS HR
Global end of trial date	22 November 2016

Results information

Result version number	v1
This version publication date	14 October 2017
First version publication date	14 October 2017

Trial information

Trial identification

Sponsor protocol code	GS-US-326-1100
-----------------------	----------------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT02520284
WHO universal trial number (UTN)	-
Other trial identifiers	Clinical Trials Registry- India: CTRI/2016/09/007304

Notes:

Sponsors

Sponsor organisation name	Gilead Sciences
Sponsor organisation address	333 Lakeside Drive, Foster City, CA, United States, 94404
Public contact	Clinical Trials Mailbox, Gilead Sciences International Ltd., ClinicalTrialDisclosures@gilead.com
Scientific contact	Clinical Trials Mailbox, Gilead Sciences International Ltd., ClinicalTrialDisclosures@gilead.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	22 November 2016
Is this the analysis of the primary completion data?	No

Global end of trial reached?	Yes
Global end of trial date	22 November 2016
Was the trial ended prematurely?	Yes

Notes:

General information about the trial

Main objective of the trial:

The primary objectives of this study were to evaluate the efficacy, safety, and tolerability of andecaliximab (GS-5745). This study was to consist of a sequential 2-part induction study (Cohort 1, Part A and Part B), a maintenance study (Cohort 2), and an optional extended treatment phase for participants who completed 52 weeks of treatment.

Protection of trial subjects:

The protocol and consent/assent forms were submitted by each investigator to a duly constituted Independent Ethics Committee (IEC) or Institutional Review Board (IRB) for review and approval before study initiation. All revisions to the consent/assent forms (if applicable) after initial IEC/IRB approval were submitted by the investigator to the IEC/IRB for review and approval before implementation in accordance with regulatory requirements.

This study was conducted in accordance with recognized international scientific and ethical standards, including but not limited to the International Conference on Harmonization guideline for Good Clinical Practice (ICH GCP) and the original principles embodied in the Declaration of Helsinki.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	15 September 2015
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	United States: 61
Country: Number of subjects enrolled	Russian Federation: 10
Country: Number of subjects enrolled	Ukraine: 9
Country: Number of subjects enrolled	Netherlands: 1
Country: Number of subjects enrolled	Poland: 23
Country: Number of subjects enrolled	Romania: 7
Country: Number of subjects enrolled	Slovakia: 1
Country: Number of subjects enrolled	United Kingdom: 6
Country: Number of subjects enrolled	Belgium: 6
Country: Number of subjects enrolled	Bulgaria: 1
Country: Number of subjects enrolled	Czech Republic: 2
Country: Number of subjects enrolled	France: 1
Country: Number of subjects enrolled	Hungary: 5

Country: Number of subjects enrolled	Ireland: 1
Country: Number of subjects enrolled	Latvia: 1
Country: Number of subjects enrolled	Korea, Republic of: 7
Country: Number of subjects enrolled	Australia: 5
Country: Number of subjects enrolled	Canada: 5
Country: Number of subjects enrolled	Italy: 4
Country: Number of subjects enrolled	New Zealand: 4
Country: Number of subjects enrolled	South Africa: 2
Country: Number of subjects enrolled	Switzerland: 2
Country: Number of subjects enrolled	Taiwan: 1
Worldwide total number of subjects	165
EEA total number of subjects	59

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	152
From 65 to 84 years	13
85 years and over	0

Subject disposition

Recruitment

Recruitment details:

Participants were enrolled at study sites in South Africa, Europe, North America, and Asia Pacific. The first participant was screened on 15 September 2015. The last study visit occurred on 22 November 2017.

Pre-assignment

Screening details:

241 participants were screened.

Period 1

Period 1 title	Blinded Induction Phase
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator

Arms

Are arms mutually exclusive?	Yes
Arm title	Andecaliximab Q2W

Arm description:

Andecaliximab 150 mg subcutaneous (SC) injection once every 2 weeks (Q2W) for a total of 4 doses alternating with matching placebo every 2 weeks

Arm type	Experimental
Investigational medicinal product name	Andecaliximab
Investigational medicinal product code	GS-5745
Other name	
Pharmaceutical forms	Injection
Routes of administration	Subcutaneous use

Dosage and administration details:

150 mg SC injection once every 2 weeks for a total of 4 doses

Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Placebo SC injection once every 2 weeks

Arm title	Andecaliximab QW
------------------	------------------

Arm description:

Andecaliximab 150 mg subcutaneous injection once weekly (QW) for a total of 8 doses

Arm type	Experimental
Investigational medicinal product name	Andecaliximab
Investigational medicinal product code	GS-5745
Other name	
Pharmaceutical forms	Injection
Routes of administration	Subcutaneous use

Dosage and administration details:

150 mg SC injection once every week for a total of 8 doses

Arm title	Placebo
------------------	---------

Arm description:

Placebo SC injection once every week

Arm type	Placebo
Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Placebo SC injection once every week

Number of subjects in period 1	Andecaliximab Q2W	Andecaliximab QW	Placebo
Started	54	56	55
Completed	52	52	53
Not completed	2	4	2
Withdrew Consent	1	1	1
Adverse event, non-fatal	1	3	-
Study Terminated by Sponsor	-	-	1

Period 2

Period 2 title	Blinded Maintenance Treatment
Is this the baseline period?	No
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator

Arms

Are arms mutually exclusive?	No
Arm title	Andecaliximab Q2W

Arm description:

Andecaliximab 150 mg SC injection once every 2 weeks for a total of 4 doses alternating with matching placebo every 2 weeks

Arm type	Experimental
Investigational medicinal product name	Andecaliximab
Investigational medicinal product code	GS-5745
Other name	
Pharmaceutical forms	Injection
Routes of administration	Subcutaneous use

Dosage and administration details:

150 mg SC injection once every 2 weeks

Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	

Pharmaceutical forms	Injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Placebo SC injection once every 2 weeks

Arm title	Andecaliximab QW
------------------	------------------

Arm description:

Andecaliximab 150 mg subcutaneous injection once weekly for a total of 8 doses

Arm type	Experimental
Investigational medicinal product name	Andecaliximab
Investigational medicinal product code	GS-5745
Other name	
Pharmaceutical forms	Injection
Routes of administration	Subcutaneous use

Dosage and administration details:

150 mg SC injection once every week for a total of 8 doses

Arm title	Placebo
------------------	---------

Arm description:

Placebo SC injection weekly

Arm type	Placebo
Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Placebo SC injection once every week

Number of subjects in period 2	Andecaliximab Q2W	Andecaliximab QW	Placebo
Started	20	16	18
Completed	0	0	0
Not completed	20	16	18
Adverse event, non-fatal	1	1	-
Disease Worsening	2	2	3
Study Terminated by Sponsor	17	11	15
Disposition Error	-	2	-

Period 3

Period 3 title	Open-Label Maintenance Phase
Is this the baseline period?	No
Allocation method	Non-randomised - controlled
Blinding used	Not blinded

Arms

Are arms mutually exclusive?	No
Arm title	Open-Label Andecaliximab QW from Andecaliximab Q2W

Arm description:

Participants from the Andecaliximab Q2W group in the induction period, who did not achieve EBS clinical remission and/or MCS response based on Week 8 assessments (Week 8 nonresponders) received open-label andecaliximab 150 mg weekly for up to 51 weeks

Arm type	Experimental
Investigational medicinal product name	Andecaliximab
Investigational medicinal product code	GS-5745
Other name	
Pharmaceutical forms	Injection
Routes of administration	Subcutaneous use

Dosage and administration details:

150 mg SC injection once every week for up to 51 weeks

Arm title	Open-Label Andecaliximab QW from Andecaliximab QW
------------------	---

Arm description:

Participants from the Andecaliximab QW group in the induction period, who did not achieve EBS clinical remission and/or MCS response based on Week 8 assessments (Week 8 nonresponders) received open-label andecaliximab 150 mg weekly for up to 51 weeks.

Arm type	Experimental
Investigational medicinal product name	Andecaliximab
Investigational medicinal product code	GS-5745
Other name	
Pharmaceutical forms	Injection
Routes of administration	Subcutaneous use

Dosage and administration details:

150 mg SC injection once a week for up to 51 weeks

Arm title	Open-Label Andecaliximab QW from Placebo
------------------	--

Arm description:

Participants from the Placebo group in the induction period, who did not achieve EBS clinical remission and/or MCS response based on Week 8 assessments (Week 8 nonresponders) received open-label andecaliximab 150 mg weekly for up to 51 weeks.

Arm type	Experimental
Investigational medicinal product name	Andecaliximab
Investigational medicinal product code	GS-5745
Other name	
Pharmaceutical forms	Injection
Routes of administration	Subcutaneous use

Dosage and administration details:

150 mg SC injection once every week for up to 51 weeks

Number of subjects in period 3	Open-Label Andecaliximab QW from Andecaliximab Q2W	Open-Label Andecaliximab QW from Andecaliximab QW	Open-Label Andecaliximab QW from Placebo
Started	20	35	34
Completed	0	0	0
Not completed	32	35	34
Withdrew Consent	3	4	2
Adverse event, non-fatal	2	1	3
Investigator's Discretion	2	1	1
Study Terminated by Sponsor	25	29	28
Joined	12	0	0
ebs	12	-	-

Baseline characteristics

Reporting groups

Reporting group title	Andecaliximab Q2W
Reporting group description: Andecaliximab 150 mg subcutaneous (SC) injection once every 2 weeks (Q2W) for a total of 4 doses alternating with matching placebo every 2 weeks	
Reporting group title	Andecaliximab QW
Reporting group description: Andecaliximab 150 mg subcutaneous injection once weekly (QW) for a total of 8 doses	
Reporting group title	Placebo
Reporting group description: Placebo SC injection once every week	

Reporting group values	Andecaliximab Q2W	Andecaliximab QW	Placebo
Number of subjects	54	56	55
Age categorical			
Units: Subjects			

Age continuous			
Safety Analysis Set includes all participants who took at least 1 dose of study drug in the Induction Study.			
Units: years			
arithmetic mean	44	43	43
standard deviation	± 14.1	± 13.2	± 12.8
Gender categorical			
Units: Subjects			
Female	19	18	24
Male	35	38	31
Race			
Units: Subjects			
White	48	48	45
Black	4	3	3
Asian	2	4	4
Native Hawaiian or Pacific	0	0	1
Not Permitted	0	0	1
Other	0	1	1
Ethnicity			
Units: Subjects			
Hispanic or Latino	0	0	2
Not Hispanic or Latino	54	56	51
Not Permitted	0	0	2

Reporting group values	Total		
Number of subjects	165		
Age categorical			
Units: Subjects			

Age continuous			
Safety Analysis Set includes all participants who took at least 1 dose of study drug in the Induction Study.			
Units: years arithmetic mean standard deviation	-		
Gender categorical			
Units: Subjects			
Female	61		
Male	104		
Race			
Units: Subjects			
White	141		
Black	10		
Asian	10		
Native Hawaiian or Pacific	1		
Not Permitted	1		
Other	2		
Ethnicity			
Units: Subjects			
Hispanic or Latino	2		
Not Hispanic or Latino	161		
Not Permitted	2		

End points

End points reporting groups

Reporting group title	Andecaliximab Q2W
Reporting group description: Andecaliximab 150 mg subcutaneous (SC) injection once every 2 weeks (Q2W) for a total of 4 doses alternating with matching placebo every 2 weeks	
Reporting group title	Andecaliximab QW
Reporting group description: Andecaliximab 150 mg subcutaneous injection once weekly (QW) for a total of 8 doses	
Reporting group title	Placebo
Reporting group description: Placebo SC injection once every week	
Reporting group title	Andecaliximab Q2W
Reporting group description: Andecaliximab 150 mg SC injection once every 2 weeks for a total of 4 doses alternating with matching placebo every 2 weeks	
Reporting group title	Andecaliximab QW
Reporting group description: Andecaliximab 150 mg subcutaneous injection once weekly for a total of 8 doses	
Reporting group title	Placebo
Reporting group description: Placebo SC injection weekly	
Reporting group title	Open-Label Andecaliximab QW from Andecaliximab Q2W
Reporting group description: Participants from the Andecaliximab Q2W group in the induction period, who did not achieve EBS clinical remission and/or MCS response based on Week 8 assessments (Week 8 nonresponders) received open-label andecaliximab 150 mg weekly for up to 51 weeks	
Reporting group title	Open-Label Andecaliximab QW from Andecaliximab QW
Reporting group description: Participants from the Andecaliximab QW group in the induction period, who did not achieve EBS clinical remission and/or MCS response based on Week 8 assessments (Week 8 nonresponders) received open-label andecaliximab 150 mg weekly for up to 51 weeks.	
Reporting group title	Open-Label Andecaliximab QW from Placebo
Reporting group description: Participants from the Placebo group in the induction period, who did not achieve EBS clinical remission and/or MCS response based on Week 8 assessments (Week 8 nonresponders) received open-label andecaliximab 150 mg weekly for up to 51 weeks.	

Primary: For Cohort 1, percentage of participants with endoscopy, rectal bleeding, and stool frequency (EBS) Clinical Remission at Week 8

End point title	For Cohort 1, percentage of participants with endoscopy, rectal bleeding, and stool frequency (EBS) Clinical Remission at Week 8 ^[1]
End point description: EBS clinical remission was defined as an endoscopic subscore of 0 or 1, rectal bleeding subscore of 0, and at least a one point decrease in stool frequency from baseline to achieve a subscore of 0 or 1. Full Analysis Set: all randomized participants who take at least 1 dose of study drug in the Induction Study (Cohort 1).	
End point type	Primary
End point timeframe: Week 8	

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Due to termination of the study, no statistical comparison was performed.

End point values	Andecaliximab Q2W	Andecaliximab QW	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	54	56	55	
Units: Percentage of participants				
number (confidence interval 95%)	7.4 (2.1 to 17.9)	1.8 (0 to 9.6)	7.3 (2 to 17.6)	

Statistical analyses

No statistical analyses for this end point

Secondary: For Cohort 1, percentage of participants with Mayo Clinic Score (MCS) Remission at Week 8

End point title	For Cohort 1, percentage of participants with Mayo Clinic Score (MCS) Remission at Week 8
-----------------	---

End point description:

1) Mayo clinic score was composed of subscores from endoscopy, rectal bleeding, stool frequency, and PGA. Mayo clinic score remission was defined as a MCS of ≤ 2 points and no individual subscore > 1 point.

2) Full Analysis Set

End point type	Secondary
----------------	-----------

End point timeframe:

Week 8

End point values	Andecaliximab Q2W	Andecaliximab QW	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	54	56	55	
Units: Percentage of participants				
number (not applicable)	7.4	1.8	7.3	

Statistical analyses

No statistical analyses for this end point

Secondary: For Cohort 1, percentage of participants achieving MCS response at Week 8

End point title	For Cohort 1, percentage of participants achieving MCS response at Week 8
-----------------	---

End point description:

1) Mayo clinic score response was defined as a MCS reduction of ≥ 3 points and at least 30% from

baseline, with an accompanying decrease in rectal bleeding subscore of ≥ 1 point or an absolute rectal bleeding subscore of 0 or 1.

2) Full Analysis Set

End point type	Secondary
End point timeframe:	
Week 8	

End point values	Andecaliximab Q2W	Andecaliximab QW	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	54	56	55	
Units: Percentage of participants				
number (not applicable)	46.3	30.4	30.9	

Statistical analyses

No statistical analyses for this end point

Secondary: For Cohort 1, percentage of participants achieving endoscopic remission (endoscopic subscore of 0) at Week 8

End point title	For Cohort 1, percentage of participants achieving endoscopic remission (endoscopic subscore of 0) at Week 8
End point description:	
Endoscopic remission was defined as an endoscopic subscore of 0.	
End point type	Secondary
End point timeframe:	
Week 8	

End point values	Andecaliximab Q2W	Andecaliximab QW	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	54	56	55	
Units: Percentage of participants				
number (not applicable)	3.7	0	5.5	

Statistical analyses

No statistical analyses for this end point

Secondary: For Cohort 1, percentage of participants achieving endoscopic response (endoscopic subscore 0 or 1) at Week 8

End point title	For Cohort 1, percentage of participants achieving endoscopic response (endoscopic subscore 0 or 1) at Week 8
-----------------	---

End point description:

- 1) Endoscopic response was defined as an endoscopic subscore of 0 or 1.
- 2) Full analysis Set

End point type	Secondary
----------------	-----------

End point timeframe:

Week 8

End point values	Andecaliximab Q2W	Andecaliximab QW	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	54	56	55	
Units: Percentage of participants				
number (not applicable)	18.5	7.1	14.5	

Statistical analyses

No statistical analyses for this end point

Secondary: For Cohort 1: percentage of participants achieving mucosal healing as determined by the Geboes histologic scoring system at Week 8

End point title	For Cohort 1: percentage of participants achieving mucosal healing as determined by the Geboes histologic scoring system at Week 8
-----------------	--

End point description:

- 1) Mucosal healing was defined as elimination of ulcers/erosion, elimination of crypt destruction, elimination of intraepithelial neutrophils, elimination of lamina propria neutrophils, and reduction in lamina propria chronic inflammatory cells to at most a mild increase. When measured by the Geboes histologic scoring system, it was the selection of the following combined scores of ≤ 3 for Grade 0 (Structural Architectural Change), ≤ 1 for Grade 1 (Chronic Inflammatory Infiltrate), ≤ 3 for Grade 2A (Lamina Propria Eosinophils), and 0 for Grade 2B (Lamina Propria Neutrophils), Grade 3 (Neutrophils in Epithelium), Grade 4 (Crypt Destruction), and Grade 5 (Erosion or Ulceration).
- 2) Full Analysis Set
- 3) For calculating the percentage of participants achieving mucosal healing as determined by Geboes histologic scoring system, only participants who did not meet the mucosal healing definition at baseline were included.

End point type	Secondary
----------------	-----------

End point timeframe:

Week 8

End point values	Andecaliximab Q2W	Andecaliximab QW	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	50	51	50	
Units: Percentage of participants				
number (not applicable)	18	13.7	22	

Statistical analyses

No statistical analyses for this end point

Secondary: For Cohort 1: percentage of participants achieving remission as defined by MCS remission (alternative definition) at Week 8

End point title	For Cohort 1: percentage of participants achieving remission as defined by MCS remission (alternative definition) at Week 8
-----------------	---

End point description:

1) Mayo clinic score remission (alternative definition) was defined as a rectal bleeding, stool frequency, and PGA subscore of 0, and an endoscopic subscore of 0 or 1 for an overall MCS of ≤ 1 .

2) Full Analysis Set

End point type	Secondary
----------------	-----------

End point timeframe:

Week 8

End point values	Andecaliximab Q2W	Andecaliximab QW	Placebo	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	54	56	55	
Units: Percentage participants				
number (not applicable)	1.9	0	0	

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Induction Period: First dose of andecaliximab to Week 8;

Double-Blind (DB) Period: First dose of andecaliximab to Week 52 plus 30 days;

Open-Label (OL) Period: First dose of open-label andecaliximab to Week 52 plus 30 days

Adverse event reporting additional description:

Safety data in general was summarized by the following analysis periods by treatment group: 1.

Induction Period (All Subjects) 2. DB Treatment Period (Wk 8 Responders; included safety data collected for these subjects between Week 0 and Wk 8 in the induction period, as well as the DB maintenance phase) 3. OL Maintenance Period (Wk 8 Nonresponders)

Assessment type	Systematic
-----------------	------------

Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	19.1
--------------------	------

Reporting groups

Reporting group title	Induction Andecaliximab Q2W
-----------------------	-----------------------------

Reporting group description:

1) Andecaliximab 150 mg SC injection once every 2 weeks for a total of 4 doses

2) Adverse events (AE) reported in this group occurred during the Induction with Additional Dose Period (Baseline to Week 8): any AEs with an onset date on or after the induction study start date and no later than 30 days after permanent discontinuation of study drug if discontinued in this period, any AEs with an onset date on or after the induction study start date and before Week 9 dosing date and no later than 30 days after the Week 8 additional dosing date, and any AEs leading to premature discontinuation.

Reporting group title	Induction Andecaliximab QW
-----------------------	----------------------------

Reporting group description:

1) Andecaliximab 150 mg SC injection once every week for a total of 8 doses

2) Adverse events reported in this group occurred during the Induction with Additional Dose Period (Baseline to Week 8): any AEs with an onset date on or after the induction study start date and no later than 30 days after permanent discontinuation of study drug if discontinued in this period, any AEs with an onset date on or after the induction study start date and before Week 9 dosing date and no later than 30 days after the Week 8 additional dosing date, and any AEs leading to premature discontinuation.

Reporting group title	Induction Placebo
-----------------------	-------------------

Reporting group description:

1) Placebo SC injection once every week up to 8 weeks

2) Adverse events (AE) reported in this group occurred during the Induction with Additional Dose Period (Baseline to Week 8): any AEs with an onset date on or after the induction study start date and no later than 30 days after permanent discontinuation of study drug if discontinued in this period, any AEs with an onset date on or after the induction study start date and before Week 9 dosing date and no later than 30 days after the Week 8 additional dosing date, and any AEs leading to premature discontinuation.

Reporting group title	Double-Blind Maintenance Andecaliximab Q2W
-----------------------	--

Reporting group description:

1) Andecaliximab 150 mg SC injection once every 2 weeks for up to 52 weeks

2) Adverse events reported in this group occurred during the Induction or Double-Blind Periods (Baseline to Week 52 plus 30 days): any AEs with an onset date on or after the double-blinded study drug start date and no later than EITHER 30 days after permanent discontinuation of double-blinded study drug if not switched to OL treatment, OR the first dose date of OL dose if switched.

Reporting group title	Double-Blind Maintenance Andecaliximab QW
-----------------------	---

Reporting group description:

1) Andecaliximab 150 mg subcutaneous injection once every week for up to 52 weeks

2) Adverse events reported in this group occurred during the Induction or Double-Blind Periods (Baseline to Week 52 plus 30 days): any AEs with an onset date on or after the double-blinded study drug start date and no later than EITHER 30 days after permanent discontinuation of double-blinded study drug if not switched to OL treatment, OR the first dose date of OL dose if switched.

Reporting group title	Double-Blind Maintenance Placebo
-----------------------	----------------------------------

Reporting group description:

- 1) Placebo SC injection once every week for up to 52 weeks
- 2) Adverse events reported in this group occurred during the Induction or Double-Blind Periods (Baseline to Week 52 plus 30 days): any AEs with an onset date on or after the double-blinded study drug start date and no later than EITHER 30 days after permanent discontinuation of double-blinded study drug if not switched to OL treatment, OR the first dose date of OL dose if switched

Reporting group title	Open-Label Andecaliximab QW from Andecaliximab Q2W
-----------------------	--

Reporting group description:

- 1) Participants from the Andecaliximab Q2W group in the induction period, who switched to open-label treatment after Week 8 assessment and received open-label andecaliximab 150 mg weekly up to 51 weeks.
- 2) Adverse events reported in this group occurred during the Open-Label Period (Study drug start during open-label to Week 52 plus 30 days): any AEs with an onset date on or after the open-label study drug start date and no later than 30 days after permanent discontinuation of open-label study drug.

Reporting group title	Open-Label Andecaliximab QW from Andecaliximab QW
-----------------------	---

Reporting group description:

- 1) Participants from the Andecaliximab QW group in the induction period, who switched to open-label treatment after Week 8 assessment and received open-label andecaliximab 150 mg weekly up to 51 weeks.
- 2) Adverse events for Open-Label Period (Study drug start during open-label to Week 52 plus 30 days) were any AEs with an onset date on or after the open-label study drug start date and no later than 30 days after permanent discontinuation of open-label study drug.

Reporting group title	Open-Label Andecaliximab QW from Placebo
-----------------------	--

Reporting group description:

- 1) Participants from the placebo group in the induction period, who switched to open-label treatment after Week 8 assessment and received open-label andecaliximab 150 mg weekly up to 51 weeks.
- 2) Adverse events for Open-Label Period (Study drug start during open-label to Week 52 plus 30 days) were any AEs with an onset date on or after the open-label study drug start date and no later than 30 days after permanent discontinuation of open-label study drug.

Serious adverse events	Induction Andecaliximab Q2W	Induction Andecaliximab QW	Induction Placebo
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 54 (0.00%)	2 / 56 (3.57%)	1 / 55 (1.82%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events			
Cardiac disorders			
Angina pectoris			
subjects affected / exposed	0 / 54 (0.00%)	1 / 56 (1.79%)	0 / 55 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Cerebrovascular accident			
subjects affected / exposed	0 / 54 (0.00%)	0 / 56 (0.00%)	0 / 55 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
Anaemia			

subjects affected / exposed	0 / 54 (0.00%)	1 / 56 (1.79%)	0 / 55 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Colitis ulcerative			
subjects affected / exposed	0 / 54 (0.00%)	0 / 56 (0.00%)	0 / 55 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Inguinal hernia			
subjects affected / exposed	0 / 54 (0.00%)	0 / 56 (0.00%)	0 / 55 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
Biliary dilatation			
subjects affected / exposed	0 / 54 (0.00%)	0 / 56 (0.00%)	0 / 55 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Nephrolithiasis			
subjects affected / exposed	0 / 54 (0.00%)	0 / 56 (0.00%)	0 / 55 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Anal abscess			
subjects affected / exposed	0 / 54 (0.00%)	0 / 56 (0.00%)	1 / 55 (1.82%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cytomegalovirus infection			
subjects affected / exposed	0 / 54 (0.00%)	0 / 56 (0.00%)	0 / 55 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	Double-Blind Maintenance Andecaliximab Q2W	Double-Blind Maintenance Andecaliximab QW	Double-Blind Maintenance Placebo
Total subjects affected by serious adverse events			

subjects affected / exposed	1 / 20 (5.00%)	2 / 16 (12.50%)	1 / 18 (5.56%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events			
Cardiac disorders			
Angina pectoris			
subjects affected / exposed	0 / 20 (0.00%)	1 / 16 (6.25%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Cerebrovascular accident			
subjects affected / exposed	0 / 20 (0.00%)	0 / 16 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	0 / 20 (0.00%)	0 / 16 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Colitis ulcerative			
subjects affected / exposed	1 / 20 (5.00%)	0 / 16 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Inguinal hernia			
subjects affected / exposed	0 / 20 (0.00%)	1 / 16 (6.25%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
Biliary dilatation			
subjects affected / exposed	0 / 20 (0.00%)	0 / 16 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Nephrolithiasis			

subjects affected / exposed	0 / 20 (0.00%)	0 / 16 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Anal abscess			
subjects affected / exposed	0 / 20 (0.00%)	0 / 16 (0.00%)	1 / 18 (5.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cytomegalovirus infection			
subjects affected / exposed	0 / 20 (0.00%)	0 / 16 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	Open-Label Andecaliximab QW from Andecaliximab Q2W	Open-Label Andecaliximab QW from Andecaliximab QW	Open-Label Andecaliximab QW from Placebo
Total subjects affected by serious adverse events			
subjects affected / exposed	1 / 32 (3.13%)	3 / 35 (8.57%)	2 / 34 (5.88%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events			
Cardiac disorders			
Angina pectoris			
subjects affected / exposed	0 / 32 (0.00%)	0 / 35 (0.00%)	0 / 34 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Cerebrovascular accident			
subjects affected / exposed	0 / 32 (0.00%)	0 / 35 (0.00%)	1 / 34 (2.94%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	0 / 32 (0.00%)	0 / 35 (0.00%)	0 / 34 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			

Colitis ulcerative			
subjects affected / exposed	1 / 32 (3.13%)	1 / 35 (2.86%)	1 / 34 (2.94%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Inguinal hernia			
subjects affected / exposed	0 / 32 (0.00%)	0 / 35 (0.00%)	0 / 34 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
Biliary dilatation			
subjects affected / exposed	0 / 32 (0.00%)	0 / 35 (0.00%)	1 / 34 (2.94%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Nephrolithiasis			
subjects affected / exposed	0 / 32 (0.00%)	1 / 35 (2.86%)	0 / 34 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Anal abscess			
subjects affected / exposed	0 / 32 (0.00%)	0 / 35 (0.00%)	0 / 34 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cytomegalovirus infection			
subjects affected / exposed	0 / 32 (0.00%)	1 / 35 (2.86%)	0 / 34 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	Induction Andecaliximab Q2W	Induction Andecaliximab QW	Induction Placebo
Total subjects affected by non-serious adverse events			
subjects affected / exposed	24 / 54 (44.44%)	31 / 56 (55.36%)	26 / 55 (47.27%)
Vascular disorders			

Hypertension subjects affected / exposed occurrences (all)	0 / 54 (0.00%) 0	1 / 56 (1.79%) 1	0 / 55 (0.00%) 0
General disorders and administration site conditions			
Fatigue subjects affected / exposed occurrences (all)	1 / 54 (1.85%) 1	1 / 56 (1.79%) 1	3 / 55 (5.45%) 3
Feeling hot subjects affected / exposed occurrences (all)	0 / 54 (0.00%) 0	0 / 56 (0.00%) 0	1 / 55 (1.82%) 1
Influenza like illness subjects affected / exposed occurrences (all)	0 / 54 (0.00%) 0	0 / 56 (0.00%) 0	1 / 55 (1.82%) 1
Injection site bruising subjects affected / exposed occurrences (all)	1 / 54 (1.85%) 2	4 / 56 (7.14%) 4	0 / 55 (0.00%) 0
Injection site erythema subjects affected / exposed occurrences (all)	0 / 54 (0.00%) 0	1 / 56 (1.79%) 1	0 / 55 (0.00%) 0
Injection site hypersensitivity subjects affected / exposed occurrences (all)	1 / 54 (1.85%) 1	0 / 56 (0.00%) 0	0 / 55 (0.00%) 0
Peripheral swelling subjects affected / exposed occurrences (all)	0 / 54 (0.00%) 0	0 / 56 (0.00%) 0	1 / 55 (1.82%) 1
Pyrexia subjects affected / exposed occurrences (all)	1 / 54 (1.85%) 1	4 / 56 (7.14%) 4	1 / 55 (1.82%) 1
Thirst subjects affected / exposed occurrences (all)	0 / 54 (0.00%) 0	0 / 56 (0.00%) 0	0 / 55 (0.00%) 0
Immune system disorders			
Hypersensitivity subjects affected / exposed occurrences (all)	0 / 54 (0.00%) 0	0 / 56 (0.00%) 0	0 / 55 (0.00%) 0
Reproductive system and breast disorders			

Menstrual disorder subjects affected / exposed occurrences (all)	0 / 54 (0.00%) 0	0 / 56 (0.00%) 0	0 / 55 (0.00%) 0
Uterine prolapse subjects affected / exposed occurrences (all)	0 / 54 (0.00%) 0	1 / 56 (1.79%) 1	0 / 55 (0.00%) 0
Respiratory, thoracic and mediastinal disorders			
Cough subjects affected / exposed occurrences (all)	1 / 54 (1.85%) 1	3 / 56 (5.36%) 3	1 / 55 (1.82%) 1
Dyspnoea subjects affected / exposed occurrences (all)	0 / 54 (0.00%) 0	1 / 56 (1.79%) 1	0 / 55 (0.00%) 0
Upper respiratory tract inflammation subjects affected / exposed occurrences (all)	1 / 54 (1.85%) 1	0 / 56 (0.00%) 0	0 / 55 (0.00%) 0
Psychiatric disorders			
Depression subjects affected / exposed occurrences (all)	1 / 54 (1.85%) 1	0 / 56 (0.00%) 0	1 / 55 (1.82%) 1
Investigations			
Blood creatine phosphokinase increased subjects affected / exposed occurrences (all)	1 / 54 (1.85%) 1	0 / 56 (0.00%) 0	2 / 55 (3.64%) 2
Haemoglobin decreased subjects affected / exposed occurrences (all)	0 / 54 (0.00%) 0	0 / 56 (0.00%) 0	0 / 55 (0.00%) 0
Lymphocyte count decreased subjects affected / exposed occurrences (all)	1 / 54 (1.85%) 1	0 / 56 (0.00%) 0	0 / 55 (0.00%) 0
Hypophosphataemia subjects affected / exposed occurrences (all)	0 / 54 (0.00%) 0	1 / 56 (1.79%) 1	0 / 55 (0.00%) 0
Iron deficiency subjects affected / exposed occurrences (all)	1 / 54 (1.85%) 1	1 / 56 (1.79%) 1	0 / 55 (0.00%) 0

Injury, poisoning and procedural complications			
Injection related reaction			
subjects affected / exposed	0 / 54 (0.00%)	0 / 56 (0.00%)	2 / 55 (3.64%)
occurrences (all)	0	0	2
Radius fracture			
subjects affected / exposed	1 / 54 (1.85%)	0 / 56 (0.00%)	1 / 55 (1.82%)
occurrences (all)	1	0	1
Nervous system disorders			
Dizziness			
subjects affected / exposed	0 / 54 (0.00%)	1 / 56 (1.79%)	1 / 55 (1.82%)
occurrences (all)	0	1	1
Headache			
subjects affected / exposed	2 / 54 (3.70%)	4 / 56 (7.14%)	1 / 55 (1.82%)
occurrences (all)	3	4	1
Lethargy			
subjects affected / exposed	0 / 54 (0.00%)	0 / 56 (0.00%)	1 / 55 (1.82%)
occurrences (all)	0	0	1
Polyneuropathy			
subjects affected / exposed	0 / 54 (0.00%)	1 / 56 (1.79%)	0 / 55 (0.00%)
occurrences (all)	0	1	0
Sciatica			
subjects affected / exposed	0 / 54 (0.00%)	0 / 56 (0.00%)	0 / 55 (0.00%)
occurrences (all)	0	0	0
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	4 / 54 (7.41%)	4 / 56 (7.14%)	2 / 55 (3.64%)
occurrences (all)	4	4	2
Thrombocytosis			
subjects affected / exposed	0 / 54 (0.00%)	0 / 56 (0.00%)	0 / 55 (0.00%)
occurrences (all)	0	0	0
Ear and labyrinth disorders			
Ear discomfort			
subjects affected / exposed	0 / 54 (0.00%)	0 / 56 (0.00%)	0 / 55 (0.00%)
occurrences (all)	0	0	0
Eye disorders			

Dry eye			
subjects affected / exposed	0 / 54 (0.00%)	0 / 56 (0.00%)	0 / 55 (0.00%)
occurrences (all)	0	0	0
Gastrointestinal disorders			
Abdominal discomfort			
subjects affected / exposed	0 / 54 (0.00%)	0 / 56 (0.00%)	1 / 55 (1.82%)
occurrences (all)	0	0	1
Abdominal distension			
subjects affected / exposed	0 / 54 (0.00%)	1 / 56 (1.79%)	1 / 55 (1.82%)
occurrences (all)	0	1	2
Abdominal pain			
subjects affected / exposed	1 / 54 (1.85%)	2 / 56 (3.57%)	5 / 55 (9.09%)
occurrences (all)	1	2	5
Colitis ulcerative			
subjects affected / exposed	2 / 54 (3.70%)	3 / 56 (5.36%)	1 / 55 (1.82%)
occurrences (all)	2	3	1
Dyschezia			
subjects affected / exposed	0 / 54 (0.00%)	1 / 56 (1.79%)	0 / 55 (0.00%)
occurrences (all)	0	1	0
Frequent bowel movements			
subjects affected / exposed	0 / 54 (0.00%)	0 / 56 (0.00%)	1 / 55 (1.82%)
occurrences (all)	0	0	1
Haematochezia			
subjects affected / exposed	1 / 54 (1.85%)	0 / 56 (0.00%)	1 / 55 (1.82%)
occurrences (all)	1	1	1
Haemorrhoids			
subjects affected / exposed	0 / 54 (0.00%)	0 / 56 (0.00%)	0 / 55 (0.00%)
occurrences (all)	0	0	0
Inguinal hernia			
subjects affected / exposed	0 / 54 (0.00%)	0 / 56 (0.00%)	0 / 55 (0.00%)
occurrences (all)	0	0	0
Mouth ulceration			
subjects affected / exposed	2 / 54 (3.70%)	2 / 56 (3.57%)	0 / 55 (0.00%)
occurrences (all)	2	2	0
Nausea			

subjects affected / exposed	2 / 54 (3.70%)	3 / 56 (5.36%)	3 / 55 (5.45%)
occurrences (all)	2	3	3
Rectal haemorrhage			
subjects affected / exposed	1 / 54 (1.85%)	0 / 56 (0.00%)	0 / 55 (0.00%)
occurrences (all)	1	0	0
Skin and subcutaneous tissue disorders			
Acne			
subjects affected / exposed	0 / 54 (0.00%)	1 / 56 (1.79%)	0 / 55 (0.00%)
occurrences (all)	0	1	0
Alopecia			
subjects affected / exposed	0 / 54 (0.00%)	1 / 56 (1.79%)	0 / 55 (0.00%)
occurrences (all)	0	1	0
Dry skin			
subjects affected / exposed	1 / 54 (1.85%)	0 / 56 (0.00%)	1 / 55 (1.82%)
occurrences (all)	1	0	1
Erythema			
subjects affected / exposed	0 / 54 (0.00%)	2 / 56 (3.57%)	0 / 55 (0.00%)
occurrences (all)	0	2	0
Erythema nodosum			
subjects affected / exposed	0 / 54 (0.00%)	0 / 56 (0.00%)	0 / 55 (0.00%)
occurrences (all)	0	0	0
Night sweats			
subjects affected / exposed	1 / 54 (1.85%)	1 / 56 (1.79%)	0 / 55 (0.00%)
occurrences (all)	1	1	0
Onychoclasia			
subjects affected / exposed	0 / 54 (0.00%)	1 / 56 (1.79%)	0 / 55 (0.00%)
occurrences (all)	0	1	0
Psoriasis			
subjects affected / exposed	0 / 54 (0.00%)	1 / 56 (1.79%)	0 / 55 (0.00%)
occurrences (all)	0	1	0
Rash			
subjects affected / exposed	1 / 54 (1.85%)	0 / 56 (0.00%)	0 / 55 (0.00%)
occurrences (all)	1	0	0
Skin lesion			
subjects affected / exposed	0 / 54 (0.00%)	1 / 56 (1.79%)	1 / 55 (1.82%)
occurrences (all)	0	1	1

Renal and urinary disorders			
Haematuria			
subjects affected / exposed	0 / 54 (0.00%)	0 / 56 (0.00%)	0 / 55 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	1 / 54 (1.85%)	3 / 56 (5.36%)	3 / 55 (5.45%)
occurrences (all)	1	3	3
Back pain			
subjects affected / exposed	1 / 54 (1.85%)	3 / 56 (5.36%)	2 / 55 (3.64%)
occurrences (all)	1	3	2
Muscle spasms			
subjects affected / exposed	0 / 54 (0.00%)	1 / 56 (1.79%)	2 / 55 (3.64%)
occurrences (all)	0	1	2
Muscular weakness			
subjects affected / exposed	0 / 54 (0.00%)	0 / 56 (0.00%)	0 / 55 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal discomfort			
subjects affected / exposed	0 / 54 (0.00%)	0 / 56 (0.00%)	0 / 55 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal stiffness			
subjects affected / exposed	0 / 54 (0.00%)	0 / 56 (0.00%)	1 / 55 (1.82%)
occurrences (all)	0	0	1
Pain in jaw			
subjects affected / exposed	0 / 54 (0.00%)	0 / 56 (0.00%)	0 / 55 (0.00%)
occurrences (all)	0	0	0
Infections and infestations			
Cellulitis			
subjects affected / exposed	1 / 54 (1.85%)	0 / 56 (0.00%)	0 / 55 (0.00%)
occurrences (all)	1	0	0
Clostridium difficile infection			
subjects affected / exposed	0 / 54 (0.00%)	0 / 56 (0.00%)	0 / 55 (0.00%)
occurrences (all)	0	0	0
Folliculitis			
subjects affected / exposed	0 / 54 (0.00%)	1 / 56 (1.79%)	1 / 55 (1.82%)
occurrences (all)	0	1	1

Gastroenteritis subjects affected / exposed occurrences (all)	0 / 54 (0.00%) 0	0 / 56 (0.00%) 0	0 / 55 (0.00%) 0
Nasopharyngitis subjects affected / exposed occurrences (all)	2 / 54 (3.70%) 2	2 / 56 (3.57%) 3	2 / 55 (3.64%) 2
Rhinitis subjects affected / exposed occurrences (all)	0 / 54 (0.00%) 0	0 / 56 (0.00%) 0	0 / 55 (0.00%) 0
Sinusitis subjects affected / exposed occurrences (all)	0 / 54 (0.00%) 0	3 / 56 (5.36%) 3	0 / 55 (0.00%) 0
Urinary tract infection subjects affected / exposed occurrences (all)	2 / 54 (3.70%) 2	2 / 56 (3.57%) 2	0 / 55 (0.00%) 0
Metabolism and nutrition disorders Decreased appetite subjects affected / exposed occurrences (all)	0 / 54 (0.00%) 0	0 / 56 (0.00%) 0	1 / 55 (1.82%) 1
Fluid retention subjects affected / exposed occurrences (all)	0 / 54 (0.00%) 0	0 / 56 (0.00%) 0	1 / 55 (1.82%) 1
Hyperglycaemia subjects affected / exposed occurrences (all)	0 / 54 (0.00%) 0	4 / 56 (7.14%) 4	1 / 55 (1.82%) 1

Non-serious adverse events	Double-Blind Maintenance Andecaliximab Q2W	Double-Blind Maintenance Andecaliximab QW	Double-Blind Maintenance Placebo
Total subjects affected by non-serious adverse events subjects affected / exposed	12 / 20 (60.00%)	12 / 16 (75.00%)	13 / 18 (72.22%)
Vascular disorders Hypertension subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	1 / 16 (6.25%) 1	0 / 18 (0.00%) 0
General disorders and administration site conditions Fatigue			

subjects affected / exposed	1 / 20 (5.00%)	1 / 16 (6.25%)	2 / 18 (11.11%)
occurrences (all)	1	1	1
Feeling hot			
subjects affected / exposed	0 / 20 (0.00%)	0 / 16 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
Influenza like illness			
subjects affected / exposed	1 / 20 (5.00%)	0 / 16 (0.00%)	1 / 18 (5.56%)
occurrences (all)	1	0	1
Injection site bruising			
subjects affected / exposed	0 / 20 (0.00%)	0 / 16 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Injection site erythema			
subjects affected / exposed	0 / 20 (0.00%)	1 / 16 (6.25%)	0 / 18 (0.00%)
occurrences (all)	0	1	0
Injection site hypersensitivity			
subjects affected / exposed	1 / 20 (5.00%)	0 / 16 (0.00%)	0 / 18 (0.00%)
occurrences (all)	2	0	0
Peripheral swelling			
subjects affected / exposed	0 / 20 (0.00%)	0 / 16 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
Pyrexia			
subjects affected / exposed	1 / 20 (5.00%)	0 / 16 (0.00%)	1 / 18 (5.56%)
occurrences (all)	1	0	1
Thirst			
subjects affected / exposed	0 / 20 (0.00%)	1 / 16 (6.25%)	0 / 18 (0.00%)
occurrences (all)	0	1	0
Immune system disorders			
Hypersensitivity			
subjects affected / exposed	1 / 20 (5.00%)	0 / 16 (0.00%)	0 / 18 (0.00%)
occurrences (all)	2	0	0
Reproductive system and breast disorders			
Menstrual disorder			
subjects affected / exposed	0 / 20 (0.00%)	0 / 16 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
Uterine prolapse			

subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	1 / 16 (6.25%) 1	0 / 18 (0.00%) 0
Respiratory, thoracic and mediastinal disorders			
Cough			
subjects affected / exposed	0 / 20 (0.00%)	2 / 16 (12.50%)	0 / 18 (0.00%)
occurrences (all)	0	2	0
Dyspnoea			
subjects affected / exposed	0 / 20 (0.00%)	1 / 16 (6.25%)	0 / 18 (0.00%)
occurrences (all)	0	1	0
Upper respiratory tract inflammation			
subjects affected / exposed	1 / 20 (5.00%)	0 / 16 (0.00%)	0 / 18 (0.00%)
occurrences (all)	1	0	0
Psychiatric disorders			
Depression			
subjects affected / exposed	0 / 20 (0.00%)	0 / 16 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
Investigations			
Blood creatine phosphokinase increased			
subjects affected / exposed	1 / 20 (5.00%)	0 / 16 (0.00%)	0 / 18 (0.00%)
occurrences (all)	1	0	0
Haemoglobin decreased			
subjects affected / exposed	1 / 20 (5.00%)	0 / 16 (0.00%)	0 / 18 (0.00%)
occurrences (all)	1	0	0
Lymphocyte count decreased			
subjects affected / exposed	1 / 20 (5.00%)	0 / 16 (0.00%)	0 / 18 (0.00%)
occurrences (all)	1	0	0
Hypophosphataemia			
subjects affected / exposed	0 / 20 (0.00%)	2 / 16 (12.50%)	0 / 18 (0.00%)
occurrences (all)	0	2	0
Iron deficiency			
subjects affected / exposed	1 / 20 (5.00%)	1 / 16 (6.25%)	0 / 18 (0.00%)
occurrences (all)	1	1	0
Injury, poisoning and procedural complications			
Injection related reaction			

subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 16 (0.00%) 0	1 / 18 (5.56%) 1
Radius fracture subjects affected / exposed occurrences (all)	1 / 20 (5.00%) 1	0 / 16 (0.00%) 0	0 / 18 (0.00%) 0
Nervous system disorders			
Dizziness subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	1 / 16 (6.25%) 1	2 / 18 (11.11%) 2
Headache subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	2 / 16 (12.50%) 2	1 / 18 (5.56%) 1
Lethargy subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 16 (0.00%) 0	1 / 18 (5.56%) 1
Polyneuropathy subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	1 / 16 (6.25%) 1	0 / 18 (0.00%) 0
Sciatica subjects affected / exposed occurrences (all)	1 / 20 (5.00%) 1	0 / 16 (0.00%) 0	0 / 18 (0.00%) 0
Blood and lymphatic system disorders			
Anaemia subjects affected / exposed occurrences (all)	3 / 20 (15.00%) 3	1 / 16 (6.25%) 1	0 / 18 (0.00%) 0
Thrombocytosis subjects affected / exposed occurrences (all)	1 / 20 (5.00%) 1	0 / 16 (0.00%) 0	0 / 18 (0.00%) 0
Ear and labyrinth disorders			
Ear discomfort subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 16 (0.00%) 0	1 / 18 (5.56%) 1
Eye disorders			
Dry eye subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 16 (0.00%) 0	0 / 18 (0.00%) 0
Gastrointestinal disorders			

Abdominal discomfort			
subjects affected / exposed	0 / 20 (0.00%)	0 / 16 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
Abdominal distension			
subjects affected / exposed	0 / 20 (0.00%)	1 / 16 (6.25%)	1 / 18 (5.56%)
occurrences (all)	0	1	2
Abdominal pain			
subjects affected / exposed	1 / 20 (5.00%)	0 / 16 (0.00%)	1 / 18 (5.56%)
occurrences (all)	1	0	1
Colitis ulcerative			
subjects affected / exposed	2 / 20 (10.00%)	1 / 16 (6.25%)	4 / 18 (22.22%)
occurrences (all)	2	1	4
Dyschezia			
subjects affected / exposed	0 / 20 (0.00%)	1 / 16 (6.25%)	0 / 18 (0.00%)
occurrences (all)	0	1	0
Frequent bowel movements			
subjects affected / exposed	0 / 20 (0.00%)	1 / 16 (6.25%)	0 / 18 (0.00%)
occurrences (all)	0	1	0
Haematochezia			
subjects affected / exposed	1 / 20 (5.00%)	1 / 16 (6.25%)	0 / 18 (0.00%)
occurrences (all)	1	1	0
Haemorrhoids			
subjects affected / exposed	0 / 20 (0.00%)	1 / 16 (6.25%)	1 / 18 (5.56%)
occurrences (all)	0	1	1
Inguinal hernia			
subjects affected / exposed	0 / 20 (0.00%)	1 / 16 (6.25%)	0 / 18 (0.00%)
occurrences (all)	0	1	0
Mouth ulceration			
subjects affected / exposed	1 / 20 (5.00%)	0 / 16 (0.00%)	0 / 18 (0.00%)
occurrences (all)	1	0	0
Nausea			
subjects affected / exposed	0 / 20 (0.00%)	0 / 16 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Rectal haemorrhage			
subjects affected / exposed	0 / 20 (0.00%)	0 / 16 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1

Skin and subcutaneous tissue disorders			
Acne			
subjects affected / exposed	0 / 20 (0.00%)	2 / 16 (12.50%)	0 / 18 (0.00%)
occurrences (all)	0	2	0
Alopecia			
subjects affected / exposed	0 / 20 (0.00%)	1 / 16 (6.25%)	0 / 18 (0.00%)
occurrences (all)	0	1	0
Dry skin			
subjects affected / exposed	0 / 20 (0.00%)	0 / 16 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
Erythema			
subjects affected / exposed	0 / 20 (0.00%)	1 / 16 (6.25%)	0 / 18 (0.00%)
occurrences (all)	0	1	0
Erythema nodosum			
subjects affected / exposed	1 / 20 (5.00%)	0 / 16 (0.00%)	0 / 18 (0.00%)
occurrences (all)	1	0	0
Night sweats			
subjects affected / exposed	1 / 20 (5.00%)	1 / 16 (6.25%)	0 / 18 (0.00%)
occurrences (all)	1	1	0
Onychoclasia			
subjects affected / exposed	0 / 20 (0.00%)	1 / 16 (6.25%)	0 / 18 (0.00%)
occurrences (all)	0	1	0
Psoriasis			
subjects affected / exposed	0 / 20 (0.00%)	1 / 16 (6.25%)	0 / 18 (0.00%)
occurrences (all)	0	1	0
Rash			
subjects affected / exposed	1 / 20 (5.00%)	0 / 16 (0.00%)	1 / 18 (5.56%)
occurrences (all)	1	0	1
Skin lesion			
subjects affected / exposed	0 / 20 (0.00%)	1 / 16 (6.25%)	0 / 18 (0.00%)
occurrences (all)	0	1	0
Renal and urinary disorders			
Haematuria			
subjects affected / exposed	1 / 20 (5.00%)	0 / 16 (0.00%)	0 / 18 (0.00%)
occurrences (all)	1	0	0
Musculoskeletal and connective tissue disorders			

Arthralgia			
subjects affected / exposed	1 / 20 (5.00%)	3 / 16 (18.75%)	3 / 18 (16.67%)
occurrences (all)	1	3	3
Back pain			
subjects affected / exposed	0 / 20 (0.00%)	1 / 16 (6.25%)	0 / 18 (0.00%)
occurrences (all)	0	1	0
Muscle spasms			
subjects affected / exposed	0 / 20 (0.00%)	1 / 16 (6.25%)	2 / 18 (11.11%)
occurrences (all)	0	1	2
Muscular weakness			
subjects affected / exposed	0 / 20 (0.00%)	1 / 16 (6.25%)	0 / 18 (0.00%)
occurrences (all)	0	1	0
Musculoskeletal discomfort			
subjects affected / exposed	0 / 20 (0.00%)	0 / 16 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
Musculoskeletal stiffness			
subjects affected / exposed	0 / 20 (0.00%)	0 / 16 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
Pain in jaw			
subjects affected / exposed	0 / 20 (0.00%)	0 / 16 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
Infections and infestations			
Cellulitis			
subjects affected / exposed	1 / 20 (5.00%)	0 / 16 (0.00%)	0 / 18 (0.00%)
occurrences (all)	1	0	0
Clostridium difficile infection			
subjects affected / exposed	1 / 20 (5.00%)	0 / 16 (0.00%)	0 / 18 (0.00%)
occurrences (all)	1	0	0
Folliculitis			
subjects affected / exposed	0 / 20 (0.00%)	1 / 16 (6.25%)	0 / 18 (0.00%)
occurrences (all)	0	1	0
Gastroenteritis			
subjects affected / exposed	0 / 20 (0.00%)	0 / 16 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Nasopharyngitis			

subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	2 / 16 (12.50%) 3	2 / 18 (11.11%) 2
Rhinitis			
subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	1 / 16 (6.25%) 1	0 / 18 (0.00%) 0
Sinusitis			
subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	1 / 16 (6.25%) 1	0 / 18 (0.00%) 0
Urinary tract infection			
subjects affected / exposed occurrences (all)	1 / 20 (5.00%) 1	1 / 16 (6.25%) 1	0 / 18 (0.00%) 0
Metabolism and nutrition disorders			
Decreased appetite			
subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 16 (0.00%) 0	1 / 18 (5.56%) 1
Fluid retention			
subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	0 / 16 (0.00%) 0	1 / 18 (5.56%) 1
Hyperglycaemia			
subjects affected / exposed occurrences (all)	0 / 20 (0.00%) 0	1 / 16 (6.25%) 1	0 / 18 (0.00%) 0

Non-serious adverse events	Open-Label Andecaliximab QW from Andecaliximab Q2W	Open-Label Andecaliximab QW from Andecaliximab QW	Open-Label Andecaliximab QW from Placebo
Total subjects affected by non-serious adverse events			
subjects affected / exposed	9 / 32 (28.13%)	6 / 35 (17.14%)	12 / 34 (35.29%)
Vascular disorders			
Hypertension			
subjects affected / exposed occurrences (all)	0 / 32 (0.00%) 0	0 / 35 (0.00%) 0	0 / 34 (0.00%) 0
General disorders and administration site conditions			
Fatigue			
subjects affected / exposed occurrences (all)	0 / 32 (0.00%) 2	0 / 35 (0.00%) 0	1 / 34 (2.94%) 1
Feeling hot			

subjects affected / exposed	0 / 32 (0.00%)	0 / 35 (0.00%)	0 / 34 (0.00%)
occurrences (all)	0	0	0
Influenza like illness			
subjects affected / exposed	0 / 32 (0.00%)	0 / 35 (0.00%)	0 / 34 (0.00%)
occurrences (all)	0	0	0
Injection site bruising			
subjects affected / exposed	1 / 32 (3.13%)	0 / 35 (0.00%)	0 / 34 (0.00%)
occurrences (all)	1	0	0
Injection site erythema			
subjects affected / exposed	1 / 32 (3.13%)	0 / 35 (0.00%)	0 / 34 (0.00%)
occurrences (all)	5	0	0
Injection site hypersensitivity			
subjects affected / exposed	0 / 32 (0.00%)	0 / 35 (0.00%)	0 / 34 (0.00%)
occurrences (all)	0	0	0
Peripheral swelling			
subjects affected / exposed	1 / 32 (3.13%)	0 / 35 (0.00%)	1 / 34 (2.94%)
occurrences (all)	1	0	1
Pyrexia			
subjects affected / exposed	0 / 32 (0.00%)	0 / 35 (0.00%)	0 / 34 (0.00%)
occurrences (all)	0	0	0
Thirst			
subjects affected / exposed	0 / 32 (0.00%)	0 / 35 (0.00%)	0 / 34 (0.00%)
occurrences (all)	0	0	0
Immune system disorders			
Hypersensitivity			
subjects affected / exposed	0 / 32 (0.00%)	0 / 35 (0.00%)	0 / 34 (0.00%)
occurrences (all)	0	0	0
Reproductive system and breast disorders			
Menstrual disorder			
subjects affected / exposed	0 / 32 (0.00%)	0 / 35 (0.00%)	0 / 34 (0.00%)
occurrences (all)	0	0	0
Uterine prolapse			
subjects affected / exposed	0 / 32 (0.00%)	0 / 35 (0.00%)	0 / 34 (0.00%)
occurrences (all)	0	0	0
Respiratory, thoracic and mediastinal disorders			

Cough subjects affected / exposed occurrences (all)	1 / 32 (3.13%) 1	0 / 35 (0.00%) 0	0 / 34 (0.00%) 0
Dyspnoea subjects affected / exposed occurrences (all)	0 / 32 (0.00%) 0	0 / 35 (0.00%) 0	0 / 34 (0.00%) 0
Upper respiratory tract inflammation subjects affected / exposed occurrences (all)	0 / 32 (0.00%) 0	0 / 35 (0.00%) 0	0 / 34 (0.00%) 0
Psychiatric disorders Depression subjects affected / exposed occurrences (all)	0 / 32 (0.00%) 0	0 / 35 (0.00%) 0	1 / 34 (2.94%) 1
Investigations Blood creatine phosphokinase increased subjects affected / exposed occurrences (all)	0 / 32 (0.00%) 0	0 / 35 (0.00%) 0	0 / 34 (0.00%) 0
Haemoglobin decreased subjects affected / exposed occurrences (all)	0 / 32 (0.00%) 0	0 / 35 (0.00%) 0	0 / 34 (0.00%) 0
Lymphocyte count decreased subjects affected / exposed occurrences (all)	0 / 32 (0.00%) 0	0 / 35 (0.00%) 0	0 / 34 (0.00%) 0
Hypophosphataemia subjects affected / exposed occurrences (all)	1 / 32 (3.13%) 1	0 / 35 (0.00%) 0	0 / 34 (0.00%) 0
Iron deficiency subjects affected / exposed occurrences (all)	0 / 32 (0.00%) 0	1 / 35 (2.86%) 1	0 / 34 (0.00%) 0
Injury, poisoning and procedural complications Injection related reaction subjects affected / exposed occurrences (all)	0 / 32 (0.00%) 0	0 / 35 (0.00%) 0	0 / 34 (0.00%) 0
Radius fracture subjects affected / exposed occurrences (all)	0 / 32 (0.00%) 0	0 / 35 (0.00%) 0	0 / 34 (0.00%) 0

Nervous system disorders			
Dizziness			
subjects affected / exposed	0 / 32 (0.00%)	0 / 35 (0.00%)	0 / 34 (0.00%)
occurrences (all)	0	0	0
Headache			
subjects affected / exposed	1 / 32 (3.13%)	0 / 35 (0.00%)	0 / 34 (0.00%)
occurrences (all)	1	0	0
Lethargy			
subjects affected / exposed	0 / 32 (0.00%)	0 / 35 (0.00%)	0 / 34 (0.00%)
occurrences (all)	0	0	0
Polyneuropathy			
subjects affected / exposed	0 / 32 (0.00%)	0 / 35 (0.00%)	0 / 34 (0.00%)
occurrences (all)	0	0	0
Sciatica			
subjects affected / exposed	0 / 32 (0.00%)	0 / 35 (0.00%)	0 / 34 (0.00%)
occurrences (all)	0	0	0
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	0 / 32 (0.00%)	1 / 35 (2.86%)	3 / 34 (8.82%)
occurrences (all)	0	1	3
Thrombocytosis			
subjects affected / exposed	0 / 32 (0.00%)	0 / 35 (0.00%)	0 / 34 (0.00%)
occurrences (all)	0	0	0
Ear and labyrinth disorders			
Ear discomfort			
subjects affected / exposed	0 / 32 (0.00%)	0 / 35 (0.00%)	0 / 34 (0.00%)
occurrences (all)	0	0	0
Eye disorders			
Dry eye			
subjects affected / exposed	1 / 32 (3.13%)	0 / 35 (0.00%)	0 / 34 (0.00%)
occurrences (all)	1	0	0
Gastrointestinal disorders			
Abdominal discomfort			
subjects affected / exposed	0 / 32 (0.00%)	0 / 35 (0.00%)	1 / 34 (2.94%)
occurrences (all)	0	0	1
Abdominal distension			

subjects affected / exposed	1 / 32 (3.13%)	0 / 35 (0.00%)	0 / 34 (0.00%)
occurrences (all)	1	0	0
Abdominal pain			
subjects affected / exposed	0 / 32 (0.00%)	0 / 35 (0.00%)	1 / 34 (2.94%)
occurrences (all)	0	0	1
Colitis ulcerative			
subjects affected / exposed	1 / 32 (3.13%)	1 / 35 (2.86%)	3 / 34 (8.82%)
occurrences (all)	1	1	4
Dyschezia			
subjects affected / exposed	0 / 32 (0.00%)	0 / 35 (0.00%)	0 / 34 (0.00%)
occurrences (all)	0	0	0
Frequent bowel movements			
subjects affected / exposed	0 / 32 (0.00%)	0 / 35 (0.00%)	0 / 34 (0.00%)
occurrences (all)	0	0	0
Haematochezia			
subjects affected / exposed	0 / 32 (0.00%)	0 / 35 (0.00%)	0 / 34 (0.00%)
occurrences (all)	0	0	0
Haemorrhoids			
subjects affected / exposed	0 / 32 (0.00%)	0 / 35 (0.00%)	0 / 34 (0.00%)
occurrences (all)	0	0	0
Inguinal hernia			
subjects affected / exposed	0 / 32 (0.00%)	0 / 35 (0.00%)	0 / 34 (0.00%)
occurrences (all)	0	0	0
Mouth ulceration			
subjects affected / exposed	0 / 32 (0.00%)	0 / 35 (0.00%)	0 / 34 (0.00%)
occurrences (all)	0	0	0
Nausea			
subjects affected / exposed	0 / 32 (0.00%)	2 / 35 (5.71%)	0 / 34 (0.00%)
occurrences (all)	0	2	0
Rectal haemorrhage			
subjects affected / exposed	0 / 32 (0.00%)	0 / 35 (0.00%)	1 / 34 (2.94%)
occurrences (all)	0	0	1
Skin and subcutaneous tissue disorders			
Acne			
subjects affected / exposed	0 / 32 (0.00%)	0 / 35 (0.00%)	0 / 34 (0.00%)
occurrences (all)	0	0	0

Alopecia			
subjects affected / exposed	0 / 32 (0.00%)	0 / 35 (0.00%)	1 / 34 (2.94%)
occurrences (all)	0	0	1
Dry skin			
subjects affected / exposed	0 / 32 (0.00%)	0 / 35 (0.00%)	0 / 34 (0.00%)
occurrences (all)	0	0	0
Erythema			
subjects affected / exposed	0 / 32 (0.00%)	0 / 35 (0.00%)	0 / 34 (0.00%)
occurrences (all)	0	0	0
Erythema nodosum			
subjects affected / exposed	0 / 32 (0.00%)	0 / 35 (0.00%)	0 / 34 (0.00%)
occurrences (all)	0	0	0
Night sweats			
subjects affected / exposed	0 / 32 (0.00%)	0 / 35 (0.00%)	0 / 34 (0.00%)
occurrences (all)	0	0	0
Onychoclasia			
subjects affected / exposed	0 / 32 (0.00%)	0 / 35 (0.00%)	0 / 34 (0.00%)
occurrences (all)	0	0	0
Psoriasis			
subjects affected / exposed	0 / 32 (0.00%)	0 / 35 (0.00%)	0 / 34 (0.00%)
occurrences (all)	0	0	0
Rash			
subjects affected / exposed	1 / 32 (3.13%)	0 / 35 (0.00%)	0 / 34 (0.00%)
occurrences (all)	1	0	0
Skin lesion			
subjects affected / exposed	0 / 32 (0.00%)	0 / 35 (0.00%)	0 / 34 (0.00%)
occurrences (all)	0	0	0
Renal and urinary disorders			
Haematuria			
subjects affected / exposed	0 / 32 (0.00%)	0 / 35 (0.00%)	0 / 34 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	0 / 32 (0.00%)	2 / 35 (5.71%)	1 / 34 (2.94%)
occurrences (all)	0	2	1
Back pain			

subjects affected / exposed	0 / 32 (0.00%)	0 / 35 (0.00%)	1 / 34 (2.94%)
occurrences (all)	0	0	1
Muscle spasms			
subjects affected / exposed	1 / 32 (3.13%)	0 / 35 (0.00%)	0 / 34 (0.00%)
occurrences (all)	1	0	0
Muscular weakness			
subjects affected / exposed	0 / 32 (0.00%)	0 / 35 (0.00%)	0 / 34 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal discomfort			
subjects affected / exposed	0 / 32 (0.00%)	0 / 35 (0.00%)	0 / 34 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal stiffness			
subjects affected / exposed	0 / 32 (0.00%)	0 / 35 (0.00%)	0 / 34 (0.00%)
occurrences (all)	0	0	0
Pain in jaw			
subjects affected / exposed	0 / 32 (0.00%)	0 / 35 (0.00%)	0 / 34 (0.00%)
occurrences (all)	0	0	0
Infections and infestations			
Cellulitis			
subjects affected / exposed	0 / 32 (0.00%)	0 / 35 (0.00%)	0 / 34 (0.00%)
occurrences (all)	0	0	0
Clostridium difficile infection			
subjects affected / exposed	0 / 32 (0.00%)	0 / 35 (0.00%)	0 / 34 (0.00%)
occurrences (all)	0	0	0
Folliculitis			
subjects affected / exposed	0 / 32 (0.00%)	0 / 35 (0.00%)	0 / 34 (0.00%)
occurrences (all)	0	0	0
Gastroenteritis			
subjects affected / exposed	0 / 32 (0.00%)	0 / 35 (0.00%)	2 / 34 (5.88%)
occurrences (all)	0	0	2
Nasopharyngitis			
subjects affected / exposed	1 / 32 (3.13%)	1 / 35 (2.86%)	0 / 34 (0.00%)
occurrences (all)	1	1	0
Rhinitis			
subjects affected / exposed	0 / 32 (0.00%)	0 / 35 (0.00%)	0 / 34 (0.00%)
occurrences (all)	0	0	0

Sinusitis			
subjects affected / exposed	0 / 32 (0.00%)	1 / 35 (2.86%)	1 / 34 (2.94%)
occurrences (all)	0	3	1
Urinary tract infection			
subjects affected / exposed	0 / 32 (0.00%)	0 / 35 (0.00%)	1 / 34 (2.94%)
occurrences (all)	0	0	1
Metabolism and nutrition disorders			
Decreased appetite			
subjects affected / exposed	0 / 32 (0.00%)	0 / 35 (0.00%)	0 / 34 (0.00%)
occurrences (all)	0	0	0
Fluid retention			
subjects affected / exposed	0 / 32 (0.00%)	0 / 35 (0.00%)	0 / 34 (0.00%)
occurrences (all)	0	0	0
Hyperglycaemia			
subjects affected / exposed	0 / 32 (0.00%)	0 / 35 (0.00%)	0 / 34 (0.00%)
occurrences (all)	0	0	0

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
29 May 2015	<ol style="list-style-type: none">1. Clarified that physician's global assessment is measured at baseline and part of eligibility criteria2. Updated immunomodulator and vedolizumab minimum duration of treatment prior therapy as part of the eligibility criteria3. Updated steroid tapering to include a reduction range from 2.5 mg/week to 5 mg/week4. Clarified that albumin is analyzed as part of the chemistry panel
27 October 2015	<ol style="list-style-type: none">1. Added evaluation of sustained MCS clinical remission, and definition of sustained MCS clinical remission, under secondary objectives and endpoints2. Added evaluation of corticosteroid-free EBS clinical remission for at least 24 weeks prior to Week 52 under secondary objectives and endpoints3. Added a 70% TNF-α antagonist treatment cap to Cohort 2 open-label induction phase enrollment and removed cap from Cohort 2 blinded maintenance phase randomization4. Clarified golimumab dose/exposure in inclusion criteria5. Added treatment with tacrolimus and apheresis therapy to exclusion criteria and prohibited concomitant medication6. Specified that compliance phone call for stool frequency and rectal bleeding documentation should occur approximately 4 days after the screening visit7. Clarified that if a colonoscopy was performed at screening, a flexible sigmoidoscopy was not required8. Clarified that 3 biopsy samples must be collected at screening9. Added instruction to remind subjects to complete documentation of dosing log for subjects dosing at home10. Removed lack of efficacy from the list of AEs/serious adverse events (SAEs) to be collected11. Added AEs arising from occupational exposure to special situation reporting requirements12. Added collection of microbiome sample to study procedures table13. Applied stopping rules and follow-up visit requirement for disease worsening to open-label maintenance phase14. Clarified that study medication may be discontinued if a subject experiences exclusionary medical conditions
29 February 2016	<ol style="list-style-type: none">1. Added an extended treatment phase for subjects completing Cohort 1 and Cohort 2 and described timing of study visits, procedures, and analyses specific to this phase2. Clarified randomization stratification3. Added methotrexate as an approved immunomodulator and concomitant UC medication in the inclusion criteria4. Clarified screening of new subjects once the 70% cap on prior TNF-α antagonist therapy was met5. Clarified inclusion criteria to specify that females were to be nonpregnant and nonlactating6. Clarified collection time points for the optional PK substudy7. Clarified screening visit assessments

13 June 2016	<ol style="list-style-type: none"> 1. Clarified disease worsening discontinuation criteria as it related to subject discontinuation and follow-up requirements during the open-label maintenance or extended treatment phase 2. Updated the name and contact information for the Gilead study director and medical monitor 3. Revised inclusion criteria to specify subject requirements for prior immunomodulator, TNF-α agonist, or vedolizumab therapy in order to clarify criteria for an inadequate clinical response to these therapies 4. Revised exclusion criteria to exclude subjects with known hypersensitivity to any components of the investigational medicinal product 5. Made exclusionary laboratory parameters for liver panel values more restrictive (> 2 times the upper limit of the normal range [ULN]) 6. Revised exclusion criteria to clarify temporal restriction for prior treatment with tacrolimus and apheresis 7. Clarified that subjects requiring dose increases to allowed UC medications during the induction phase would be discontinued from the study 8. Defined mucosal healing for the purposes of study evaluation 9. Clarified UC medications allowed during the open-label maintenance and extended treatment phases of the study 10. Specified that investigational drugs for the treatment of UC were prohibited during the study 11. Specified clinical laboratory analytes to be evaluated and antibody/antigen tests to be conducted
--------------	--

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? Yes

Date	Interruption	Restart date
21 September 2016	After the first 150 subjects completed the 8-week induction phase, the data monitoring committee (DMC) for this Study conducted a protocol-specified interim analysis. After review, the DMC recommended that the study be terminated due to meeting the prespecified futility and efficacy criteria. Effective 21 September 2016, Study GS-US-326-1100 was terminated. Part B of Cohort 1 and Cohort 2 were not enrolled.	-

Notes:

Limitations and caveats

Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.

The DMC recommended that the study be terminated due to meeting the prespecified futility & efficacy criteria. Due to termination of the study, no formal statistical testing was planned for the final analysis.

Notes: